Trials / Not Yet Recruiting
Not Yet RecruitingNCT07011589
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- M. Peter Marinkovich · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
Conditions
- Epidermolysis Bullosa (EB)
- Epidermolysis Bullosa Acquisita
- Recessive Dystrophic Epidermolysis Bullosa
- Dystrophic Epidermolysis Bullosa
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Efgartigimod | Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-07-01
- Completion
- 2026-10-01
- First posted
- 2025-06-09
- Last updated
- 2025-06-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07011589. Inclusion in this directory is not an endorsement.